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Abstract
Background: An increased incidence of deep venous thrombosis (DVT) has been described in
multiple myeloma (MM). A recently described mechanism of hypercoagulability in cancer patients
including MM patients is acquired activated protein C resistance (APC-R). The purpose of the
present study was to examine the association between the combination of thalidomide plus
chemotherapy and DVT development in a cohort of patients with newly diagnosed multiple
myeloma. We also evaluated the association between acquired activated protein C resistance and
DVT.
Methods: Patients with newly diagnosed and symptomatic MM (untreated or with one cycle of
preceding chemotherapy) were evaluated. The present study is a prospective, descriptive,
longitudinal and observational one. The coagulations tests were performed including: prothrombin
time, activated partial thromboplastic time (aPTT), fibrinogen, anticardiolipin antibodies, lupus
anticoagulant, antithrombin, protein C and protein S activities, factor VIII, activated protein C
(APC) resistance, factor V Leiden, and quantitative D-dimers. Factor V Leiden mutation was
detected by analysis of the polymerase chain reaction amplification of genomic DNA.
Results: Fifty newly diagnosed multiple myeloma patients were included in the study. DVT was
developed in 8 patients (16%). Six patients were confirmed to have acquired activated C protein
resistance. All of them were tested twice. Four out of 6 patients developed DVT (66%), all of them
received thalidomide at a median dose of 200 mg qd.
Conclusion: APC-R appears to be a transitional condition that may be related to myeloma status.
Thrombotic complications can affect morbidity and even mortality in these patients. To fully
evaluate the potential synergistic anticancer activity of combinations of chemotherapy and
thalidomide, effective prophylactic anticoagulation should be implemented in all controlled trials, at
least during the first few cycles of treatment.
Background
Recent reports of an increased incidence of venous throm-
boembolic events (VTE) in patients with multiple mye-
loma (MM) have sparked interest in hypercoagulability
associated with hematologic malignancies and immu-
nomodulator therapy [1]. A recently described mecha-
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nism of hypercoagulability in cancer patients including
MM patients is acquired activated protein C resistance
(APC-R) [2]. The fact that APC-R is not secondary to factor
V Leiden has been described in up to 8% of all APC-R
patients with aetiologies including oral contraceptives,
pregnancy, anti-prothrombin antibodies, lupus anticoag-
ulants, anti-phosphatidyl-ethanolamine antibodies and
anti-protein S antibodies. APC-R remains an independent
risk factor for VTE, regardless of aetiology [3].
With the increasing use of thalidomide as initial therapy
for MM, deep venous thrombosis (DVT) and other throm-
botic events also have emerged as major adverse events.
Interestingly, Zangari et al (2002) reported that thalido-
mide therapy increased the risk of VTE to 50% in those
with APC-R. In a peculiar manner, the increased risk of
thrombosis in patients with MM is almost non existent
when thalidomide is used as a single agent, but risk
increases substantially when the drug is combined with
high-dose corticosteroids or certain chemotherapy drugs
[4]. The incremental risk suggests that the risk of DVT may
be related to the interaction between drugs and their col-
lective effect on malignant cells and some others events
such as APC-R or the vascular endothelium [5].
The purpose of the present study was to examine the asso-
ciation between the combination of thalidomide plus
chemotherapy and DVT development in a cohort of
patients with newly diagnosed multiple myeloma. We
also evaluated the association between acquired activated
protein C resistance and DVT.
Methods
Patients with newly diagnosed MM were evaluated. We
enrolled all patients who fulfilled entire criteria for multi-
ple myeloma during the period between January 1998
and December 2005. The present study is a prospective,
descriptive, longitudinal and observational one. We col-
lected clinical data and biochemical parameters at diagno-
sis and during their monitoring as inpatients and
outpatients. Clinical features included age, sex, perform-
ance status, bone pain lesions, hepato-splenomegaly and
plasmacytomas. Biochemical parameters data were col-
lected including blood count, liver function test, blood
chemistry, LDH, reactive C protein, B2-microglobulin,
urine studies (urea, Bence Jones Proteinuria and light
chains) and protein electrophoresis. Bone marrow tre-
phine biopsy was performed and immunostaining also
was included. Cytogenetics by karyotyping was evaluated.
Performance status and bone lesions were scored accord-
ing to previously described criteria. In addition, patients
were grouped into clinical stages according to Durie-
Salmon criteria. Imaging studies where performed (bone
series, CT scan and MRI) when necessary.
Treatment schemes
Thalidomide was prescribed in an oral dose of 100 mg qhs
and increased by 50 mg every 7 days to a maximum dose
of 300 mg, depending on side effects. Dexamethasone was
given in an oral dose of 20 mg/m2 each morning after
breakfast on days 1–4, 9–12 and 17–20, followed by 10
days without therapy prior to the next cycle. VAD was
given as an out-patient regimen including: vincristine (0.4
mg/day, continuous IV), doxorubicin (9 mg/m2/day, con-
tinuous IV) and dexamethasone (40 mg/day PO) with a
median of 6 courses. Melphalan and prednisolone were
prescribed in 4 days courses (M 6–9 mg/m2/day PO and
P 100 mg/day PO) at 4–6 week intervals.
Response and toxicity criteria
Response was assessed according to the European, Inter-
national, and Autologous Bone Marrow Transplant Regis-
tries (EBMT/IBMTR/ABMTR) criteria [6]. Thus, responses
were categorized as CR (negative immunofixation, <5%
bone marrow plasma cells, disappearance of soft tissue
plasmacytomas), partial response (PR) (decrease in the
M-protein > or equal to 50%, decrease in the light chain
urine protein excretion > or equal to 90% plus reduction
> or equal to 50%, in the size of soft tissue plasmacyto-
mas), or minimal response (MR) (25 to 49% decrease in
the serum M-component, 50–89% reduction in the urine
light chain protein excretion and 25 to 49% decrease in
the size of soft tissue plasmacytomas). The results were
analyzed on an intention-to-treat basis since all patients
who started treatment were included in the analysis.
Coagulations tests and thrombosis
Citrate plasma was used to investigate coagulation and
anticoagulation parameters. The coagulations tests were
performed including: prothrombin time, activated partial
thromboplastic time (aPTT), fibrinogen, anticardiolipin
antibodies, lupus anticoagulant, antithrombin III, protein
C and protein S activities, activated protein C (APC) resist-
ance, Factor V Leiden, and quantitative D-dimers. Factor V
Leiden mutation was detected by analysis of the polymer-
ase chain reaction amplification of genomic DNA. The
DNA was extracted from ethylenediamine tetraacetic acid
anticoagulated blood. APC resistance was tested using
fresh or frozen plasma stored at -70°C. The aPTT was
measured using a compact coagulometer. The APC resist-
ance was determined on citrated plasma using an aPTT-
based Food and Drug Administration-approved resistance
assay with factor V deficient plasma (Chromogenix Instru-
mentation Laboratory, Milano, Italy). The ratios between
the aPTT with or without the presence of activated protein
C were calculated. The patient was considered positive if
the ratio was less than 2. Samples that were reported pos-
itive for APC-R were retested using both, second genera-
tion assay and the original assay (Dade, Behring and
Chromogenix) to confirm the previous report.Thrombosis Journal 2006, 4:11 http://www.thrombosisjournal.com/content/4/1/11
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MM patients were regularly evaluated by the medical staff
and underwent Doppler ultrasound examination if there
were clinical signs or symptoms suggestive of DVT. The
date of DVT was defined as the date of its confirmation by
Doppler ultrasonography, which was performed on all
patients with clinical indication of DVT.
Statistical analysis
was performed using SPSS version 13.0. Fisher's exact test
was used to evaluate the statistical significance of associa-
tions in two-way contingency tables. Cochran-Mantel-
Haenszel methods were used to evaluate the association
between APC resistance and DVT occurrence while con-
trolling for thalidomide exposure. A p value of less than
0.05 was considered as statistically significant.
Results
Fifty newly diagnosed multiple myeloma patients were
included in the study, 27 (54%) male and 23 (46%)
female, aged 45–83 (mean 63). Underlying diagnosis was
IgG MM in 40 (80%), IgA in 8 (16%) and light chain dis-
ease in 2 (4%). Table 1
Median age at diagnosis was 63 years (45–83). Median
plasma cells number in marrow was 48% (23–90%). Sev-
enty five percent of patients presented bone lesions at
diagnosis. Plasmacytoma was seen in 9 patients, 2 with
extramedullary plasmacytoma. Median hemoglobin was
11.82 g/dl (8.2–14.9). B2 microglobulin was observed
with a median of 4.82 mg/L (1.2–9.6) and albumin level
expressed a median value of 3.49 g/L (2.15–4.60). Clini-
cal characteristics are seen in Table 1. According to Durie-
Salmon criteria patients were grouped into: I A (n 7,
14%), I B (n 4, 8%), IIA (n 13, 26%), II B (n 5, 10%), III
A (n 14, 28%) and III B (n 7, 14%). Table 2
Patients received as frontline therapy three different
schemes of chemotherapy. VAD scheme was given in 20
patients (40%) while thalidomide and dexamethasone
was given in 48% (24 patients). Only 6 patients (12%)
received melphalan and prednisolone. Table 3 Median
follow-up was 42 months. After 6 cycles, patients receiv-
ing thalidomide plus dexamethasone showed an overall
objective response rate of 75% while VAD group only
reached 55% (CR, NCR and PR) p0.005.
DVT was developed in 8 patients (16%). Known risk fac-
tors for DVT, such as central venous catheters (CVC)
(present in 25% patients, none developed DVT), perform-
ance status, and hormonal therapy were not significantly
different between these 2 groups of chemotherapy (all p
values > 0.2). None patient has prior history of DVT and
neither one has been receiving anticoagulation at the time
of enrollment. DVT was developed in 5 patients treated
with thalidomide plus dexamethasone, 1 patient treated
with VAD and thalidomide and 2 more receiving VAD
only. A significant shorter time to DVT was observed in
patients exposed to VAD chemotherapy (first 2 cycles p =
to 0.007). Table 4 Seven patients developed DVT in the
lower extremities and the remainder developed DVT and
pulmonary embolism.
Six patients were confirmed to have activated C protein
resistance. Lupus anticoagulant was negative in all cases.
The ratios observed in this study for APCR are shown in
Table 5. Factor VIII levels may also influence the result of
APCR. Since frequent and important elevated levels of fac-
tor VIII in MM are described, the level of factor VIII con-
comitant to APCR determination seems to be mandatory,
we found normal levels of factor VIII for patients with
APCR. In parallel, we measured D-dimers, those are
shown in Table 5. Patients positive for APC resistance
Table 3: Overall objective response according to scheme of 
therapy
Scheme N %
VAD 20 40
Overall objective response 11/20 55
Thalidomide plus dexamethasone 24 48
Overall objective response 18/24 75
Melphalan plus prednisone 6 12
Overall objective response 2/6 33
Table 1: Clinical characteristics
Gender Male 27 (54%)
Female 23 (46%)
*Age 63 (45–83 years)
*Marrow plasma cells (%) 48% (23–90%)
Immunoglobulins IgG 40 (80%)
IgA 8 (16%)
LC 2 (4%)
*Bone lesions 75%
*Creatinine mg/dl 1.5 (0.6–5.6)
*Hemoglobin (g/dl) 11.8 (8.2–14.9)
Plasmacytoma 9 (18%)
*B2 microglobulin 4.8 (1.2–9.6)
*Albumin g/L 34.9 (21.5–46)
APC-R 6 (12%)
*Levels are expressed as median values
Table 2: Stage according to Durie-Salmon
Stage N %
IA 7 14
IB 4 8
IIA 13 26
IIB 5 10
IIIA 14 28
IIIB 7 14Thrombosis Journal 2006, 4:11 http://www.thrombosisjournal.com/content/4/1/11
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were re-tested using a second generation assay and the
original assay (Dade-Behring), we found a 100% concord-
ance between both methods. Of these 6 patients four
developed DVT (66%), all of the cases received thalido-
mide at a median dose of 200 mg qd. Two patients with
APC-R did not present DVT. All cases developed the
thrombosis event during the first year of treatment, partic-
ularly during the induction phase in the VAD group (time
to thrombosis of 2.3 months versus 6.6 months for thalid-
omide plus dexamethasone). After patients achieved any
type of response according to EBMT/IBMTR/ABMTR crite-
ria, another re-test of ACP-R was performed; it was nega-
tive in 7/8. All patients received anticoagulation therapy
based on coumadin at a target INR of 2.5–3.0. Neither one
developed re-thrombosis but one patient developed sec-
ondary plasma cell leukemia. Patients who were positive
for ACP-R were tested for factor V mutation but only one
was positive for this abnormality. The patient with genetic
activated protein C resistance did not present DVT. We did
not find abnormalities in protein S and C levels at our
patients.
Discussion
High cumulative risk of thrombotic events in myeloma
patients has been already reported [7]. The present study
confirmed that myeloma patients treated with thalido-
mide and multi-agent chemotherapy are at increased risk
of DVT. Many DVT risk factors have been identified.
Alikhan et al, (2003) reported many of them [8]. With the
median follow-up of 42 months, the rate of DVT was 16%
at our study. The thrombotic phenomenon occurred early
in the course of treatment (100% during the first year at
our patients). The percentage of DVT associated with treat-
ment with thalidomide and chemotherapy including dex-
amethasone varies according to the series (4–28%), we
found an overall incidence of 12% (6/50) of DVT in
patients receiving thalidomide but when patients devel-
oped Acquired activated protein C resistance (ACP-R), the
DVT incidence increases (66%).
The possible production of auto-antibodies against pro-
tein C in these patients could be the explanation for the
transient APC resistance phenotype observed in some of
the patients [9,10]. The manufacturer recommends 1/5
dilution for the APC-R test, we used this dilution. High
titer of antibodies could still inhibit the activity of APC
based on previous reports [10]. Monoclonal immu-
noglobulins have often an antibody activity (lupus antico-
agulant or auto-antibodies against protein C have been
described) or cryoglobulin properties. Lupus anticoagu-
lant can induce false positive APCR ratio. A 1:40 dilution
seems to be the optimal dilution to avoid lupus anticoag-
ulant interference. We used 1:5 dilution, which is proba-
bly not sufficient to avoid interference of high titer
antibodies against protein C. Search for lupus anticoagu-
Table 5: Coagulation tests for newly diagnosed patients with 
multiple myeloma
Test Result
TVE 8/50 (16%)
TVE and APC-R 4/6 (66%)
APC-R 6/50 (12%)
Median ratio APC-R 6/50 1.5 (1.4–1.6)
*Factor VIII (iu/dl) 96 iu/dl (n 50)
*D-dimer (ng/ml) 456 ng/ml (n 50)
*a PTT (seconds) 29 s (n 50)
*PT (seconds) 13 s (n 50)
Antithrombin (u/dl) 99 u/dl (n 50)
Factor V Mutation 1/50 (2%)
Lupus anticoagulant 0/50
*Protein S (u/dl) 98 u/dl (n 50)
*Protein C (u/dl) 96 u/dl (n 50)
TVE Thromboembolic Events, APC-R Acquired Activated Protein C 
Resistance. * Levels are expressed as median values
Table 4: Time to thrombosis according to therapy
Patient Therapy Time to thrombosis Months APC-R Yes/Not
1T D6 Y e s
2T D7 Y e s
3T D8 Y e s
4T D6 Y e s
5 TD 6 Not
6V A D - T 3 N o t
7V A D 2 N o t
8V A D 2 N o t
p value 0.007 time to thrombosis between TD and VAD therapy.
TD: Thalidomide plus dexamethasone, VAD; Vincristine, Doxorubicin and Dexamethasone; VAD-T: VAD plus thalidomide; APC-R Acquired 
activated protein C resistance.Thrombosis Journal 2006, 4:11 http://www.thrombosisjournal.com/content/4/1/11
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lant was important in this case. Patients with APCR were
negative for lupus anticoagulant. We found only one
patient with genetic PCR who did not develop thrombo-
sis. People with the APC-R phenotype because on inher-
ited or acquired conditions usually have APC ratios below
2. Predilution of samples with factor V deficient plasma
provides 100% sensitivity for the factor V Leiden muta-
tion and reduces the influence of plasma handling,
heparin therapy and oral warfarin [11]. In order to con-
firm APC-R, samples were performed using the original
assay and the second generation assay, we found a 100%
concordance between both assays.
The activated protein C resistance (APCr) phenotype is
found in around 40% of thrombophilic Mexican Mestizo
individuals; since only very few display the factor V gene
Leiden (Arg506Gln) mutation, it was considered of inter-
est looking for other factor V gene mutations associated to
thrombophilia: The HR2 haplotype, the factor V Cam-
bridge (Arg306Thr), the factor V Hong Kong (Arg306Gly)
and the FV Liverpool (Ile359Thr). In 39 individuals, the
FV Leiden was found in 10%, the HR2 haplotype in 28%,
the FV Hong Kong in 2%, whereas the FV Cambridge and
FV Liverpool gene mutations were not found in any indi-
vidual in a Mexican population [12].
There is a strong association between DVT and exposure
to doxorubicin/thalidomide. The thrombotic mechanism
seems to be multifactorial in the DVT patients [13]. The
highest incidence of DVT is noticed during the first cycle
of doxorubicin containing chemotherapy in some other
series [14,15]. It supports the fact that tumor load and
myeloma characteristics are not the restrictive factors asso-
ciated to development of DVT. We also found better out-
comes in those patients receiving thalidomide plus
dexamethasone than VAD receivers according to some
other reports [16-18]. In conclusion, it is clear that in mul-
tiple myeloma thalidomide increases the thrombotic risk,
particularly in combination with chemotherapy and APC-
R could be an additional factor associated to the DVT
pathogenesis. APC-R appears to be a transitional condi-
tion may be related to myeloma status. Thrombotic com-
plications can affect morbidity and even mortality in these
patients. To fully evaluate the potential synergistic anti-
cancer activity of combinations of chemotherapy and tha-
lidomide, effective prophylactic anticoagulation should
be implemented in all controlled trials, at least during the
first few cycles of treatment.
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